Navigation Links
Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity
Date:12/9/2010

ATLANTA, Dec. 9, 2010 /PRNewswire/ -- Customers using Elekta's MOSAIQ® oncology information system (OIS) experience success with seamless integration to Varian's TrueBeam system for radiation therapy delivery. The MOSAIQ interface to this linear accelerator is the most recent example of exceptional connectivity between Elekta's premier OIS and the delivery systems of other cancer management equipment providers, including Siemens and TomoTherapy, and particle therapy vendors such as Hitachi and IBA.

"Creating a seamless link between MOSAIQ and TrueBeam is consistent with Elekta's philosophy of open systems connectivity that has endured for 20 years," says Todd Powell, Executive Vice President, Elekta Software. "MOSAIQ provides unsurpassed safety, functionality and interoperability, meeting our clinicians' highest expectations and providing the most comprehensive information medium for excellent patient care."

The MOSAIQ OIS streamlines medical oncology and radiation oncology workflow from the first encounter, through diagnosis and staging, planning, treatment and long-term follow-up. At the heart of MOSAIQ is the image-enabled electronic medical record (EMR) by which healthcare professionals communicate information about their patients throughout the continuum of cancer care.

First centers with new MOSAIQ connectivity report success

Long Island Jewish (LIJ) Medical Center (New Hyde Park, N.Y.) and Exempla Saint Joseph Comprehensive Cancer Center (Denver, Colo.) are among the first sites to use the new MOSAIQ OIS interface with the TrueBeam system. Both centers have experienced excellent MOSAIQ connectivity and interoperability.  

"Three years ago we converted to a 100 percent paperless department, and accomplished this by modifying departmental workflow into an integral process-driven patient care operation in MOSAIQ," says Louis Potters, M.D., Chairman, Department of Radiation Medicine North Shore-LIJ Health System. "The MOSAIQ software offers more than an EMR. It provides an entire radiation oncology solution that manages patient data and the department's operations. As we rebuilt our department, MOSAIQ was a great product to start with. In addition, MOSAIQ interfaces with some components of our other hospital systems. All-in-all, the MOSAIQ experience with the latest Varian linac is a success for our patients and for our ability to maintain a progressive electronic environment in a complex busy academic practice."

Clinicians at LIJ also are looking forward to upgrading to the next MOSAIQ release, version 2.2, Dr. Potters adds.

"From what I've seen, MOSAIQ 2.2 offers even more ways to streamline workflow as well as a few improvements to existing modules," he says.

The MOSAIQ interface to TrueBeam has been in place at Exempla Saint Joseph Comprehensive Cancer Center for a few months, according to Greg Gibbs, Consultant Physicist.

"The TrueBeam system connected terrifically from the beginning as did Exempla's other two Varian linear accelerators previously—there were no problems at all," he says. "It's important to have similar user environments at each linac since the therapists go between machines. Since MOSAIQ offers the finest user experience, provides the broadest interoperability and is the most feature-rich OIS available, we were always confident it would satisfy our needs. Historically, Elekta's EMR has been superior and has led its product category since the beginning."

Leveraging more than 20 years of leadership and expertise of IMPAC Medical Systems, MOSAIQ continues to set the standard for connectivity and usability in the most advanced cancer care facilities in the world. More than 1,400 global customers count on Elekta software to help them provide the safest and most efficient treatments in the fight against cancer. From its multiple redundant safety features to industry-leading practice management capabilities, MOSAIQ is the tool of choice to manage cutting-edge treatment centers.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):